Login to Your Account

Following in Pharmasset's Footsteps?

Inhibitex Soars on Early HCV Data; Phase II Combos Next

By Jennifer Boggs
Managing Editor

Monday, November 7, 2011

Shares of Inhibitex Inc. skyrocketed a whopping 130 percent Friday after top-line data from an early hepatitis C virus (HCV) study indicated INHX-189's potential as a monotherapy, putting the Atlanta-based company hot on the trail of the interferon-free HCV regimen vanguard.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription